Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Albumins
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Paclitaxel

abstract

  • NAB-paclitaxel 125 mg/m(2) administered on days 1, 8, and 15 of a 28-day cycle was well tolerated and demonstrated encouraging single-agent activity. No corticosteroid premedication was administered and no hypersensitivity reactions were seen. Additional studies of single-agent NAB-paclitaxel as well as platinum-based combinations are warranted.

publication date

  • February 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.10.8605

PubMed ID

  • 18235124

Additional Document Info

start page

  • 639

end page

  • 43

volume

  • 26

number

  • 4